177Lu-PSMA-617与紫杉烷化疗后转移性去势抵抗性前列腺癌患者的肾功能下降:倾向评分分析
本研究比较了177Lu-PSMA-617放射配体治疗与多西他赛化疗对mCRPC患者肾功能的影响。经倾向评分调整后,治疗后早期两组肾功能下降无差异;长期随访中两组肾功能下降总体发生率均增加,但基线肾功能保留者无变化,而慢性肾病患者下降更显著。
要点
- 经倾向评分调整后,RPT与化疗在治疗后6个月肾功能下降无差异。
- 长期随访中两组肾功能下降总体发生率均增加,但基线肾功能保留者无变化。
- 慢性肾病患者的肾功能下降显著大于基线肾功能保留者。
核心结论
- 经倾向评分调整后,肾功能下降在基线肾功能较低的患者中最为普遍,mCRPC患者的肾功能下降可能并非仅由177Lu-PSMA-617治疗引起。
研究设计与样本
- 研究采用比较与反事实分析,纳入接受至少3且不超过6周期177Lu-PSMA-617联合雄激素剥夺治疗或完成6周期多西他赛(联合或不联合雄激素剥夺治疗)的患者,要求每个治疗周期有30天窗口内的血清肌酐和eGFR测量。
- 通过1:1匹配、逆概率加权和优势加权方法减少组间选择偏倚,并对序贯接受两种治疗的患者进行反事实分析。
主要发现
- 经倾向评分调整后,治疗后早期(6个月)RPT组与化疗组肾功能恶化无差异,RPT组中位eGFR从82降至80 mL/min/1.73 m2,两组P=0.49。
- 长期随访中,两组肾功能下降总体发生率均增加(P=0.044),RPT组中位eGFR从82降至72 mL/min/1.73 m2。
- 分层分析显示基线肾功能保留者无变化(P=0.49),而慢性肾病患者肾功能下降显著更大(P=0.0023)。
- 同一患者内,6周期RPT与6周期化疗相比肾功能保持稳定。
临床怎么用
- 对于mCRPC患者,尤其是基线肾功能较低者,接受177Lu-PSMA-617治疗时应关注肾功能变化。
- 基线肾功能保留的患者在177Lu-PSMA-617治疗期间肾功能可能保持稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a study to determine the effects of 177Lu-PSMA-617 treatment on renal function decline in patients with metastatic castration-resistant prostate cancer (mCRPC) shortly after treatment and over long-term follow-up. Methods: The study used comparative and counterfactual analysis. Patients were eligible for inclusion if they received at least 3 but no more than 6 cycles of 177Lu-PSMA-617 with androgen-deprivation therapy or completed 6 cycles of docetaxel with or without androgen-deprivation therapy. Further, the availability of serum creatinine and estimated glomerular filtration rate (eGFR) measurements within a 30-d window for each treatment cycle was required. A decline in eGFR of greater than 3 mL/min/1.73 m2/year was assessed by comparing baseline values with the posttreatment eGFR and the last available follow-up eGFR. The incidence of eGFR decline was compared between patients who received radiopharmaceutical therapy (RPT) and those who received chemotherapy after 1:1 matching, inverse probability weighting, and weighting by odds method to reduce intergroup selection bias with an additional counterfactual analysis of patients who received both treatments sequentially. Results: After propensity score adjustment using established risk factors for renal function decline, there was no difference in renal function deterioration in early posttreatment (6 mo after treatment) between patients who received RPT and those who received chemotherapy (median eGFR decreased from 82 to 80 mL/min/1.73 m2 within the RPT group, P = 0.49 in both treatment groups). During long-term follow-up, the overall incidence of renal function decline increased in both groups (P = 0.044, median eGFR fall from 82 to 72 mL/min/1.73 m2 in the RPT-treated group). Stratified analyses demonstrated no change among patients with preserved baseline renal function (P = 0.49), whereas patients with chronic kidney disease exhibited a significantly greater decline in renal function (P = 0.0023). Renal function remained stable over 6 cycles of RPT compared with 6 cycles of chemotherapy within the same patients. Conclusion: After adjustment of presumed risk factors, renal function decline was most prevalent in patients with lower baseline renal function. Renal function decline in patients with mCRPC, who are already susceptible to compromised renal function, may not be solely caused by 177Lu-PSMA-617 therapy.
引用
- Sheheryar N, Nikanpour Y, Manohar S, et al. Renal Function Decline After 177Lu-PSMA-617 Versus Taxane-Based Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Propensity Score Analysis. J Nucl Med. 2026. PMID: 42785953. doi:10.2967/jnumed.126.272551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。